TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01683994
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
Study: NCT01683994
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
Study: NCT02419547
Drug: Versed
Normalized name: Versed
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
Study: NCT02419547
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
Study: NCT02419547
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
Study: NCT02341144
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00763997
Drug: dipyrone
Normalized name: Dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
Study: NCT00538317
Drug: tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
Study: NCT00515723
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: randomized to 12 week trial of risperidone.
Study: NCT00515723
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomized to 12 week trial of olanzapine.
Study: NCT00515723
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomized to 12 week trial of quetiapine.
Study: NCT00515723
Drug: ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomized to 12 week trial of ziprasidone.
Study: NCT00005945
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT00005945
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03776539
Drug: ELX-02
Normalized name: ELX-02
DrugBank: ELX-02 (DB15080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
Study: NCT03883100
Drug: HQP1351
Normalized name: HQP1351
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tablet, taken orally once every other day
Study: NCT02957032
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
Study: NCT00005945
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01934790
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
Study: NCT03442023
Drug: Chlorhexidine gluconate at 2%
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
Study: NCT03442023
Drug: Chlorhexidine gluconate at 0.12%
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
Study: NCT00164177
Drug: HalfLytely
Normalized name: HalfLytely and Bisacodyl
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04616716
Drug: FMTN
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast
Study: NCT00005945
Drug: pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT00576563
Drug: FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: contrast medium
Study: NCT05216822
Drug: Racecadotril
Normalized name: racecadotril
DrugBank: Racecadotril (DB11696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
Study: NCT00507403
Drug: infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005945
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00005945
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01486602
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01486602
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT00777764
Drug: Cohort I
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI.
Study: NCT00022581
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03880253
Drug: CTP-692
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Placebo or CTP-692
Study: NCT04018274
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg by mouth (PO) once daily (QD)
Study: NCT00176982
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02748889
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy
Study: NCT02748889
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy
Study: NCT00387426
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02218606
Drug: Abiraterone acetate 1000 mg po daily
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02218606
Drug: Cabazitaxel 25 mg/m2 IV
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02218606
Drug: prednisone 5 mg po BID
Normalized name: prednisone 5 MG
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04292704
Drug: Clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole vaginal tablets
Study: NCT04056988
Drug: Perflutren Lipid Microsphere
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
Study: NCT03633747
Drug: Propranolol Hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
Study: NCT00306813
Drug: Revlimid
Normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003397
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003397
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003397
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003397
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003397
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003397
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003397
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00961467
Drug: Revlimid, Melphalan, Prednisone, Thalidomide
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thalidomide was administered at 50 mg/day.
Study: NCT00961467
Drug: Revlimid, Melphalan, Prednisone, Thalidomide
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thalidomide was administered at 100 mg/day.
Study: NCT02706405
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04394377
Drug: Group 2: control group with enoxaparin 40mg/d
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual standard of care and currently have no indication of full anticoagulation.
Study: NCT05190783
Drug: Formocresol
Normalized name: Formocresol
DrugBank: Cresol (DB11143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixture of formalin, cresol and glycerine used for fixation of pulp tissues
Study: NCT05190783
Drug: MTA
Normalized name: HMTA
DrugBank: 5'-S-methyl-5'-thioadenosine (DB02282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: material used for pulp regeneration, direct and indirect pulp capping
Study: NCT02304705
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg three times daily by mouth for 90 days
Study: NCT00204659
Drug: Rituximab + CHOP chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard Rituximab + CHOP chemo-immunotherapy
Study: NCT01603420
Drug: Luteinizing hormone-releasing hormone (LHRH)
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
Study: NCT01933243
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 4 capsules daily
Study: NCT04020185
Drug: Immune checkpoint inhibitor (ICI)
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to product label
Study: NCT01603420
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
Study: NCT00330252
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
Study: NCT00330252
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
Study: NCT02260947
Drug: PF-06273340
Normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06273340 50 mg
Study: NCT02260947
Drug: PF-06273340
Normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06273340 400 mg
Study: NCT02260947
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 300 mg
Study: NCT01704404
Drug: TD-4208
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02476006
Drug: ALIROCUMAB SAR236553 (REGN727)
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02476006
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT02476006
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT03872791
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
Study: NCT00567567
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00567567
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00567567
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00567567
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00567567
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00567567
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00567567
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00567567
Drug: Vincristine Sulfate Liposome
Normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03286218
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT03286218
Drug: Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04407689
Drug: Interleukin-7
Normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
Study: NCT01786226
Drug: Oral administration of mifepristone 2.5 mg daily for three months
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental: 1
Study: NCT01786226
Drug: Oral administration of mifepristone 5 mg daily for three months
Normalized name: bupropion
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental: 2
Study: NCT00168389
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
Study: NCT00383708
Drug: lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
Study: NCT00383708
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
Study: NCT02767635
Drug: Botox-Epic
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: injected 20 units of Botox into lateral epicondyle in Botox-Epic group
Study: NCT02767635
Drug: Botox-Tend
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: injected 20 units of Botox into tender point of muscles in Botox-Tend group
Study: NCT02767635
Drug: triamcinolone acetonide (Steroid)
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
Study: NCT02444585
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intended to prevent periprosthetic loss of bone mineral density
Study: NCT01961414
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
Study: NCT04371523
Drug: Apo-Hydroxychloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.
Study: NCT01523067
Drug: Vasomera (PB1046)
Normalized name: Vasomera
DrugBank: Vasomera (DB16498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Vasomera
Study: NCT01523067
Drug: 0.9% Sodium Chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT00861926
Drug: Ventolin
Normalized name: Ventolin
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin : salbutamol sulfate 100µg
Study: NCT00861926
Drug: beclometasone /formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BDP 100µg/FF 6µg, 1 inhalation bid
Study: NCT04396223
Drug: Avelumab Injection
Normalized name: avelumab Injection
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab administration at 800mg a 1 hour IV infusion once every 14 days during 4 months ½ (median)
Study: NCT02251171
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02251171
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02251171
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00650312
Drug: Metformin Hydrochloride ER Tablets 500 mg
Normalized name: metformin hydrochloride Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg, single dose fasting
Study: NCT03908580
Drug: Meditoxin
Normalized name: medigoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
Study: NCT02630875
Drug: A4250
Normalized name: Odevixibat
DrugBank: Odevixibat (DB16261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A4250
Study: NCT02476175
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
Study: NCT00645268
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
Study: NCT00645268
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
Study: NCT00874731
Drug: Ridaforolimus 100 mg
DrugBank: Ridaforolimus (DB06233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
Study: NCT00874731
Drug: Ridaforolimus 40 mg
DrugBank: Ridaforolimus (DB06233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
Study: NCT00338143
Drug: efalizumab
Normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00458081
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 20 mg once per day + slightly reduced calorie diet